Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Hamza Elbouny, Brahim Ouahzizi, Mohamed Bammou, Khalid Sellam & Chakib Alem. (2023) Anti-hyperlipidemic and Antioxidant Potential of Phenolic Monoterpenes Rich Thymus satureioides Coss. Volatile Oil. Journal of Biologically Active Products from Nature 13:5, pages 448-459.
Read now
Read now
Brian Tomlinson, Paul Chan, Yuzhen Zhang & Christopher Wai Kei Lam. (2020) Efficacy and safety of add on therapies in patients with hypercholesterolemia undergoing statin therapy. Expert Opinion on Pharmacotherapy 21:17, pages 2137-2151.
Read now
Read now
Mohamed M. Elseweidy, Sahar E. Elswefy, Nahla N. Younis & Shaden Tarek. (2020) The modulation of PCSK-9 and GAGs by 10-dehydrogingerdione and pentoxifylline in hyperlipidemic rabbits. Natural Product Research 34:16, pages 2372-2377.
Read now
Read now
Brian Tomlinson, Paul Chan, Yuzhen Zhang, Zhongmin Liu & Christopher Wai Kei Lam. (2020) Pharmacokinetics of current and emerging treatments for hypercholesterolemia. Expert Opinion on Drug Metabolism & Toxicology 16:5, pages 371-385.
Read now
Read now
Bogusław Okopień, Łukasz Bułdak & Aleksandra Bołdys. (2018) Benefits and risks of the treatment with fibrates––a comprehensive summary. Expert Review of Clinical Pharmacology 11:11, pages 1099-1112.
Read now
Read now
Articles from other publishers (26)
Graziano Pinna. (2023) Role of PPAR-Allopregnanolone Signaling in Behavioral and Inflammatory Gut-Brain Axis Communications. Biological Psychiatry 94:8, pages 609-618.
Crossref
Crossref
Mengya Shi, Siyu Han, Kristin Klier, Gisela Fobo, Corinna Montrone, Shixiang Yu, Makoto Harada, Ann-Kristin Henning, Nele Friedrich, Martin Bahls, Marcus Dörr, Matthias Nauck, Henry Völzke, Georg Homuth, Hans J. Grabe, Cornelia Prehn, Jerzy Adamski, Karsten Suhre, Wolfgang Rathmann, Andreas Ruepp, Johannes Hertel, Annette Peters & Rui Wang-Sattler. (2023) Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts. Cardiovascular Diabetology 22:1.
Crossref
Crossref
Zeltzin Alejandra Ceja-Galicia, Fernando Enrique García-Arroyo, Omar Emiliano Aparicio-Trejo, Mohammed El-Hafidi, Guillermo Gonzaga-Sánchez, Juan Carlos León-Contreras, Rogelio Hernández-Pando, Martha Guevara-Cruz, Armando R. Tovar, Pedro Rojas-Morales, Ana Karina Aranda-Rivera, Laura Gabriela Sánchez-Lozada, Edilia Tapia & José Pedraza-Chaverri. (2022) Therapeutic Effect of Curcumin on 5/6Nx Hypertriglyceridemia: Association with the Improvement of Renal Mitochondrial β-Oxidation and Lipid Metabolism in Kidney and Liver. Antioxidants 11:11, pages 2195.
Crossref
Crossref
Begard Berzinji & Kawa Dizaye. (2022) Investigating the effect of Fenofibrate on biomarkers of vascular inflammation in L-NAME induced hypertensive rats. Pharmacia 69:2, pages 459-465.
Crossref
Crossref
Syed J. Khundmiri, Carolyn M. Ecelbarger, Joycemary Amponsem, Hong Ji, Kathryn Sandberg & Dexter L. Lee. (2022) PPAR-α knockout leads to elevated blood pressure response to angiotensin II infusion associated with an increase in renal α-1 Na+/K+ ATPase protein expression and activity. Life Sciences 296, pages 120444.
Crossref
Crossref
Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Mitsunori Matsushita, Toshiaki Nojima, Hideki Suganami & Shun Ishibashi. (2021) Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double‐blind placebo‐controlled clinical trials. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Junyi Li, Li Zhou, Xinping Ouyang & Pingping He. (2021) Transcription Factor-7-Like-2 (TCF7L2) in Atherosclerosis: A Potential Biomarker and Therapeutic Target. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Julia Nowowiejska, Anna Baran & Iwona Flisiak. (2021) Aberrations in Lipid Expression and Metabolism in Psoriasis. International Journal of Molecular Sciences 22:12, pages 6561.
Crossref
Crossref
Robert Krysiak, Karolina Kowalcze & Bogusław Okopień. (2020) The impact of vitamin D status on cardiometabolic effects of fenofibrate in women with atherogenic dyslipidemia. Clinical and Experimental Pharmacology and Physiology 48:2, pages 186-194.
Crossref
Crossref
Juan M. León-MartínezEsperanza Martínez-AbundisManuel González-OrtizKarina G. Pérez-Rubio. (2021) Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial. Journal of Medicinal Food 24:2, pages 111-115.
Crossref
Crossref
D.D. Miceli, V.P. Vidal, M.F.C. Blatter, O.P. Pignataro & V.A. Castillo. (2021) Fenofibrate treatment for severe hypertriglyceridemia in dogs. Domestic Animal Endocrinology 74, pages 106578.
Crossref
Crossref
Jong Youl Kim, Sumit Barua, Ye Jun Jeong & Jong Eun Lee. (2020) Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease. International Journal of Molecular Sciences 21:17, pages 6419.
Crossref
Crossref
Lei Zhang, Zhi-Gang She, Hongliang Li & Xiao-Jing Zhang. (2020) Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. Clinical Science 134:13, pages 1775-1799.
Crossref
Crossref
Hiroshi Kawanishi, Koji Ohashi, Hayato Ogawa, Naoya Otaka, Tomonobu Takikawa, Lixin Fang, Yuta Ozaki, Mikito Takefuji, Toyoaki Murohara & Noriyuki Ouchi. (2020) A novel selective PPARα modulator, pemafibrate promotes ischemia-induced revascularization through the eNOS-dependent mechanisms. PLOS ONE 15:6, pages e0235362.
Crossref
Crossref
Shinji Kobuchi, Atsushi Shigemura, Yukako Ito & Toshiyuki Sakaeda. (2020) A validated LC–MS/MS method for the low-level determination of pemafibrate, a novel SPPARMα, in plasma. Bioanalysis.
Crossref
Crossref
Shih‐Wei Wang, Lung‐Chih Li, Chien‐Hao Su, Yao‐Hsu Yang, Tsuen‐Wei Hsu & Chien‐Ning Hsu. (2019) Association of Statin and Its Lipophilicity With Cardiovascular Events in Patients Receiving Chronic Dialysis. Clinical Pharmacology & Therapeutics 107:6, pages 1312-1324.
Crossref
Crossref
Yamashita, Arai, Yokote, Araki, Matsushita, Nojima, Suganami & Ishibashi. (2019) Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. International Journal of Molecular Sciences 20:22, pages 5537.
Crossref
Crossref
Ling Yi, Hua Zhang, Jin‐wen Zhang, Xiao‐ming You, Zhi‐qiang Ning, Jia Yu, Li‐fang Qian & Li‐yan Miao. (2019) Study on Drug‐Drug Interactions Between Chiglitazar, a Novel PPAR Pan‐Agonist, and Metformin Hydrochloride in Healthy Subjects. Clinical Pharmacology in Drug Development 8:7, pages 934-941.
Crossref
Crossref
Ping Yu, Wenjing Liu, Jinghui Ren, Yingying Wang, Yao Ning, Mingqi Huang, Xinyi Hu, Lili Wei, Min Ji & Jin Cai. (2019) Design, synthesis and biological evaluation of hypolipidemic compounds based on BRD4 inhibitor RVX-208. Bioorganic & Medicinal Chemistry Letters 29:16, pages 2168-2172.
Crossref
Crossref
Eiichi Araki, Shizuya Yamashita, Hidenori Arai, Koutaro Yokote, Jo Satoh, Toyoshi Inoguchi, Jiro Nakamura, Hiroshi Maegawa, Narihito Yoshioka, Yukio Tanizawa, Hirotaka Watada, Hideki Suganami & Shun Ishibashi. (2019) Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study. Diabetes, Obesity and Metabolism 21:7, pages 1737-1744.
Crossref
Crossref
Ovidiu Alin Stirban. (2019) In Stufen zu möglichst niedrigem LDL-Cholesterin bei Diabetes. Info Diabetologie 13:2, pages 35-41.
Crossref
Crossref
Koutaro Yokote, Shizuya Yamashita, Hidenori Arai, Eiichi Araki, Hideki Suganami & Shun Ishibashi. (2019) Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment. International Journal of Molecular Sciences 20:3, pages 706.
Crossref
Crossref
Anika Dutta & Neelam Sharma-Walia. (2019) Curbing Lipids: Impacts ON Cancer and Viral Infection. International Journal of Molecular Sciences 20:3, pages 644.
Crossref
Crossref
Robert Krysiak, Witold Szkróbka & Bogusław Okopień. (2019) Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. Pharmacological Reports 71:1, pages 61-66.
Crossref
Crossref
Xin Su, Yi Kong & Dao-quan Peng. (2018) New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients. Lipids in Health and Disease 17:1.
Crossref
Crossref
Nicola Tarantino, Francesco Santoro, Michele Correale, Luisa De Gennaro, Silvio Romano, Matteo Di Biase & Natale Daniele Brunetti. (2018) Fenofibrate and Dyslipidemia: Still a Place in Therapy?. Drugs 78:13, pages 1289-1296.
Crossref
Crossref